The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry
Authors:
- Joshua S. KurtzJKJoshua S. Kurtz
- Neal A PatelNPNeal A Patel
- Julian L. GendreauJulian L. Gendreau
- Chenyi YangCYChenyi Yang
- Nolan BrownNBNolan Brown
- Nick BuiNBNick Bui
- Bryce PictonBPBryce Picton
- Mark HarrisMHMark Harris
- Matthew HatterMHMatthew Hatter
- Ryan BeyerRBRyan Beyer
- Ronald SahyouniRSRonald Sahyouni
- Luis Daniel Diaz-AguilarLDLuis Daniel Diaz-Aguilar
Open Access
- 14 September 2022
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 14 (9) , e29167
Abstract
Although early therapeutic research on psychedelics dates back to the 1940s, this field of investigation was met with many cultural and legal challenges in the 1970s. Over the past two decades, clinical trials using psychedelics have resumed. Therefore, the goal of this study was to (1) better characterize the recent uptrend in psychedelics in clinical trials and (2) identify areas where potentially new clinical trials could be initiated to help in the treatment of widely prevalent medical disorders. A systematic search was conducted on the clinicaltrials.gov database for all registered clinical trials examining the use of psychedelic drugs and was both qualitatively and quantitatively assessed. Analysis of recent studies registered in clinicaltrials.gov was performed using Pearson’s correlation coefficient testing. Statistical analysis and visualization were performed using R software. In totality, 105 clinical trials met this study’s inclusion criteria. The recent uptrend in registered clinical trials studying psychedelics (p = 0.002) was similar to the uptrend in total registered clinical trials in the registry (p < 0.001). All trials took place from 2007 to 2020, with 77.1% of studies starting in 2017 or later. A majority of clinical trials were in phase 1 (53.3%) or phase 2 (25.7%). Common disorders treated include substance addiction, post-traumatic stress disorder, and major depressive disorder. Potential research gaps include studying psychedelics as a potential option for symptomatic treatment during opioid tapering. There appears to be a recent uptrend in registered clinical trials studying psychedelics, which is similar to the recent increase in overall trials registered. Potentially, more studies could be performed to evaluate the potential of psychedelics for symptomatic treatment during opioid tapering and depression refractory to selective serotonin reuptake inhibitors.Keywords
This publication has 48 references indexed in Scilit:
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybinProceedings of the National Academy of Sciences, 2012
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of opennessJournal of Psychopharmacology, 2011
- The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyJournal of Psychopharmacology, 2010
- Ranking the Harm of Alcohol, Tobacco and Illicit Drugs for the Individual and the PopulationEuropean Addiction Research, 2010
- Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosisJournal of Psychopharmacology, 2009
- Are psychedelic drug treatments seeing a comeback in psychiatry?Progress in Neurology and Psychiatry, 2008
- Can psychedelics have a role in psychiatry once again?The British Journal of Psychiatry, 2005
- Effects of the South American Psychoactive Beverage Ayahuasca on Regional Brain Electrical Activity in Humans: A Functional Neuroimaging Study Using Low-Resolution Electromagnetic TomographyNeuropsychobiology, 2004
- Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United KingdomThe British Journal of Psychiatry, 1971
- Ueber CacteenalkaloïdeEuropean Journal of Inorganic Chemistry, 1896